Clinical effectiveness of antioxidant therapy with Mexidol Fort 250 patients with chronic cerebral venous deficiency

Authors:
E.I. Chukanova, A.S. Chukanova, H.I. Mamaeva

FGAOU in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2021, T. 121, No. 3

Summary:
Purpose of the study. Studying the effectiveness and safety of the effect of complex therapy of ethylmethylhydroxypyridine with succinate (Mexidol Forte 250) and venotonic drugs of Lizinate and diosmine of hesperidine in patients with chronic cerebral venous insufficiency (CCVN). Material and methods. 120 patients with CCVN have clinical and ultrasonic signs of cerebral venous discirculation were examined. Patients are divided into 3 subgroups depending on the type of therapy. The first group (n = 40) was prescribed orally Mexidol Fort 250 and diosmine of hesperidine within 74 days in combination with the appointment of 2 courses of intravenous administration of lysinate escin (L-lysine of the escinate) on the 1st and 30th day from the beginning of treatment; The 2nd group (n = 40) was prescribed orally Mexidol Fort 250 and diosmine hesperidine for 74 days; The 3rd group (n = 40) orally prescribed the drug Diosmin Hesperidine for 74 days. Results and conclusion. The effectiveness and safety of the complex therapy of patients with CCVN venotonic drugs with the inclusion of the antioxidant drug Mexidol Forte 250 by 750 mg/day for 74 days is shown. The study demonstrates the reliable positive effect of Mexidol Forte 250 on the dynamics of complaints and indicators of the neurological and psychoemotional status of patients. Monotherapy with a venotonic drug with a diosmine of hesperidine showed its insufficient effectiveness. Keywords: chronic cerebral venous deficiency, antioxidants, Mexidol forte 250, venotonic drugs, lesinate escine, diosmine gesperidine.